drugset
drugset / Trial / NCT07075185

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

NCT07075185 ↗

Phase 1 Recruiting 70 enrolled Kelonia Therapeutics, Inc.
NaSequentialOpen-labelTreatment

Summary

The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.

Timeline

Start
2025-07-16
Primary completion
2027-03
Completion
2042-05

Drugs

EvaluationDrugModalityDoseRoute
Subject KLN-1010 Unknown — —

Indications

blood coagulation disease immunoproliferative disorder lymphoproliferative syndrome monoclonal paraproteinemia disease plasma cell myeloma vascular disorder